

CLAIMS

1. A pharmaceutical composition comprising a recombinant protein, wherein the pharmaceutical composition is a liquid formulation comprising the recombinant protein at a concentration of 50 mg/ml to 250 mg/ml histine in a concentration of 10 mM to 50 mM, proline in a concentration of 100 mM to 500 mM and a surfactant in a concentration of 0.001% to 0.1% (w/v), and wherein the recombinant protein is an antibody or an antigen-binding fragment thereof which is:
 - 1) an antibody or antigen-binding fragment thereof which:
 - a. comprises CDR-H1 having the sequence as defined in SEQ ID NO:1; CDR-H2 having the sequence as defined in SEQ ID NO:2; CDR-H3 having the sequence as defined in SEQ ID NO:3; CDR-L1 having the sequence as defined in SEQ ID NO:4; CDR-L2 having the sequence as defined in SEQ ID NO:5 and CDR-L3 having the sequence as defined in SEQ ID NO:6; or
 - b. comprises a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy variable region having the sequence as defined in SEQ ID NO: 8; or
 - c. comprises a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy chain having the sequence as defined in SEQ ID NO: 11; or
 - 2) an antibody which comprises a light chain having the sequence as defined in SEQ ID NO: 9 and a heavy chain having the sequence as defined in SEQ ID NO: 10.
2. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof, wherein the pharmaceutical composition is a liquid formulation comprising the antibody or an antigen-binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml, histidine in a concentration of 10 mM to 50 mM, proline in a concentration of 100 mM to 500 mM and a surfactant in a concentration of 0.001% to 0.1% (w/v), and wherein the antibody or an antigen-binding fragment thereof is:
 - 1) an antibody or antigen-binding fragment thereof which:
 - a. comprises CDR-H1 having the sequence as defined in SEQ ID NO:1; CDR-H2 having the sequence as defined in SEQ ID NO:2; CDR-H3 having the sequence as defined in SEQ ID NO:3; CDR-L1 having the sequence as defined in SEQ ID NO:4; CDR-L2 having the sequence as defined in SEQ ID NO:5 and CDR-L3 having the sequence as defined in SEQ ID NO:6; or

- b. comprises a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy variable region having the sequence as defined in SEQ ID NO: 8; or
 - c. comprises a light variable region having the sequence as defined in SEQ ID NO: 7 and a heavy chain having the sequence as defined in SEQ ID NO: 11; or
- 2) an antibody which comprises a light chain having the sequence as defined in SEQ ID NO: 9 and a heavy chain having the sequence as defined in SEQ ID NO: 10.
- 3. The pharmaceutical composition according to any one of the preceding claims, wherein the pH is between 5 and 7.4 or between 5 and 6.5 or between 5 and 6.
- 4. The pharmaceutical composition according to any one of the preceding claims, wherein histidine is in a concentration of 30 mM and proline is in a concentration of 250 mM, at a pH between 5.2 and 6.0
- 5. The pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is polysorbate 80, in a concentration of 0.01% to 0.05%, or of 0.03%.
- 6. The pharmaceutical composition according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is formulated at a concentration 120 mg/ml to 160 mg/ml, or of 140 mg/ml.